

C o m p a n y Representative	KYORIN Holdings, Inc. Minoru Hogawa
	Representative Director, President
	(Security Code: 4569, TSE 1st Sec.)
Contact	Shuji Miyaki
	Director, Corporate Communication President
	Office
Telephone	(0)3-3525-4707

Conclusion of Agreement with Monospharm Trade Co., Ltd. Concerning Marketing Rights for Generic Medicines

KYORIN Holdings, Inc. (Head office: Chiyoda-ku, Tokyo, Japan, President & CEO: Minoru Hogawa) announced today that its subsidiary KYORIN Rimedio Co., Ltd. (Head office: Kanazawa-shi, Ishikawa-ken, Japan, President: Hiroshi Hashizume, "KYORIN Rimedio" or the "Company") has concluded an agreement with Monospharm Trade Co., Ltd. (Head office: Ulan Bator, Mongolia, President: Erdenechimeg Luvasan, "Monospharm Trade"), which belongs to the MONOS Group, concerning marketing rights for generic medicines in Mongolia

In accordance with the agreement, KYORIN Rimedio grants Monospharm Trade marketing rights for two generic medicine products in Mongolia. Monospharm Trade will submit a drug registration application for the two products in Mongolia, acquire the registration to import and sell them promptly after obtaining drug registration approval and supply the products to medical institutions.

This is KYORIN Rimedio's first transaction with a company in Mongolia. The Company will take advantage of the conclusion of the agreement to examine the possibility of exporting other products and will promote the supply of drugs and medicines to Mongolia, contributing to the health of people around the world. The Company will also investigate the potential of local manufacturing of drugs and medicines, among other possibilities, through discussions with the MONOS Group in the future.

The impact of the subject matter on the consolidated business results for the fiscal year ending March 31, 2019 will be immaterial.

Outline of Monospharm Trade

Name of company:	Monospharm Trade Co., Ltd.
Location:	Namyanju street-2, Ulaanbaatar 210348, Mongolia
Representative:	Erdenechimeg Luvasan
Business description: The MONOS Group is the leading pharmaceutical company in Mongolia. It has license	
relationships with companies in Europe and China and engages in import transactions as	
	well as the manufacture of drugs and medicines from medical plants.